A rival drug company has severely undercut Martin Shrkeli’s position on the pricing of the drug Daraprim. Shkreli made recent news by charging $750 per pill of the drug. Now Imprimis Pharmaceuticals says that they will charge only $1 a pill and are expecting to make a lot of profit at that price. Cenk Uygur, Jimmy Dore (The Jimmy Dore Show), Lissette Padilla, and Kelly Carlin hosts of The Young Turks discuss.
Do you think this will hurt Shkreli’s business or image? Will Daraprim remain profitable at $1 a pill? Let us know in the comments below.
Read more here: http://www.businessinsider.com/a-comp…
“Almost a month after word got out that drug-company CEO Martin Shkreli had jacked up the price of a critical drug by more than 5,000%, a different kind of pharma company has stepped up to provide a cheaper alternative.
Imprimis Pharmaceuticals, a compounding pharmaceutical company, announced Thursday that it is now providing a customizable formulation to compete with Daraprim, a drug used to treat a parasitic infection called toxoplasmosis in people with compromised immune systems.
Shkreli jacked up the cost of Daraprim from $13.50 to $750 a pill seemingly overnight.”